Importantly, TSPAN1 depletion was found to sensitize resistant cells to the action of distinct therapeutic drugs (i.e., CDDP and dasatinib), and this sensitization was more pronounced in biopsy-derived primary cell lines from laryngeal and pharyngeal tumors in comparison to established HNSCC cell lines. Here, TSPAN1 is linked to head and neck squamous cell carcinoma.